Kistler Tiffany Companies LLC Sells 3,223 Shares of Celgene Co. (NASDAQ:CELG)

Kistler Tiffany Companies LLC lessened its position in shares of Celgene Co. (NASDAQ:CELG) by 44.5% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,019 shares of the biopharmaceutical company’s stock after selling 3,223 shares during the period. Kistler Tiffany Companies LLC’s holdings in Celgene were worth $399,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. First PREMIER Bank acquired a new stake in shares of Celgene in the third quarter valued at approximately $26,000. Liberty Wealth Management LLC raised its position in shares of Celgene by 212.8% in the second quarter. Liberty Wealth Management LLC now owns 294 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 200 shares in the last quarter. Weaver Consulting Group acquired a new stake in shares of Celgene in the first quarter valued at approximately $29,000. Massey Quick Simon & CO. LLC acquired a new stake in shares of Celgene in the second quarter valued at approximately $33,000. Finally, Lenox Wealth Advisors LLC acquired a new stake in shares of Celgene in the third quarter valued at approximately $37,000. Institutional investors own 72.47% of the company’s stock.

CELG has been the subject of a number of analyst reports. BidaskClub upgraded shares of Celgene from a “hold” rating to a “buy” rating in a research report on Tuesday, October 1st. Mizuho downgraded shares of Celgene from a “buy” rating to a “neutral” rating and dropped their price target for the company from $103.00 to $100.00 in a research report on Monday, August 19th. Cowen reiterated a “hold” rating and issued a $102.00 price target on shares of Celgene in a research report on Tuesday, July 30th. Zacks Investment Research upgraded shares of Celgene from a “sell” rating to a “hold” rating and set a $94.00 price target for the company in a research report on Tuesday, July 23rd. Finally, ValuEngine downgraded shares of Celgene from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, seventeen have assigned a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $94.60.

Shares of CELG opened at $102.95 on Friday. Celgene Co. has a one year low of $58.59 and a one year high of $102.13. The company has a market cap of $72.15 billion, a P/E ratio of 13.53, a P/E/G ratio of 0.52 and a beta of 1.42. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.44 and a quick ratio of 3.32. The firm has a 50 day simple moving average of $98.84 and a two-hundred day simple moving average of $95.48.

Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $2.61 EPS for the quarter, beating the consensus estimate of $2.44 by $0.17. Celgene had a net margin of 32.24% and a return on equity of 89.93%. The business had revenue of $4.40 billion during the quarter, compared to the consensus estimate of $4.22 billion. During the same period in the previous year, the business earned $2.16 earnings per share. The company’s revenue was up 15.4% on a year-over-year basis. On average, analysts expect that Celgene Co. will post 9.96 earnings per share for the current fiscal year.

In other Celgene news, insider Terrie Curran sold 11,338 shares of the business’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $98.27, for a total transaction of $1,114,185.26. Following the completion of the transaction, the insider now directly owns 13,493 shares in the company, valued at $1,325,957.11. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.39% of the stock is owned by insiders.

Celgene Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Further Reading: Is the QQQ ETF safe?

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.